Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells
- 16 November 2013
- journal article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 388 (1-2) , 25-37
Abstract
Interleukin-6 (IL-6) is the major activator of the acute phase response (APR). One important regulator of IL-6-activated APR is peroxisome proliferator-activated receptor alpha (PPARα). Currently, there is a growing interest in determining the role of PPARα in regulating APR; however, studies on the molecular mechanisms and signaling pathways implicated in mediating the effects of IL-6 on the expression of PPARα are limited. We previously revealed that IL-6 inhibits PPARα gene expression through CAAT/enhancer-binding protein transcription factors in hepatocytes. In this study, we determined that STAT1/3 was the direct downstream molecules that mediated the Janus kinase 2 (JAK2) and phosphatidylinositol-3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathways in IL-6-induced repression of PPARα. Treatment of cells with pharmacological inhibitors of JAK2, PI3K, AKT, and mTOR attenuated the inhibitory effect of IL-6 on PPARα protein in a dose-dependent manner. These inhibitors also decreased the IL-6-induced repression of PPARα mRNA expression and promoter activity. Overexpression of STAT1 and STAT3 in HepG2 cells cotransfected with a reporter vector containing this PPARα promoter region revealed that both the expression plasmids inhibited the IL-6-induced repression of PPARα promoter activity. In the presence of inhibitors of JAK2 and mTOR (AG490 and rapamycin, respectively), IL-6-regulated protein expression and DNA binding of STAT1 and STAT3 were either completely or partially inhibited simultaneously, and the IL-6-induced repression of PPARα protein and mRNA was also inhibited. This study has unraveled novel pathways by which IL-6 inhibits PPARα gene transcription, involving the modulation of JAK2/STAT1–3 and PI3K/AKT/mTOR by inducing the binding of STAT1 and STAT3 to STAT-binding sites on the PPARα promoter. Together, these findings represent a new model of IL-6-induced suppression of PPARα expression by inducing STAT1 and STAT3 phosphorylation and subsequent down-regulation of PPARα mRNA expression.Keywords
This publication has 85 references indexed in Scilit:
- Hepatic acute phase proteins – Regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signalingEuropean Journal of Cell Biology, 2012
- PI3K and STAT3: A New AllianceCancer Discovery, 2011
- Roles of activated astrocyte in neural stem cell proliferation and differentiationStem Cell Research, 2011
- The Effects of Injury Magnitude on the Kinetics of the Acute Phase ResponseJournal of Trauma: Injury, Infection & Critical Care, 2011
- The Regulation of Liver Cell Survival by ComplementThe Journal of Immunology, 2009
- The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle eventsMolecular Neurodegeneration, 2009
- STAT3 and STAT1 mediate IL-11–dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant miceJournal of Clinical Investigation, 2008
- Effects of Hepatocyte Nuclear Factor-4α on the Regulation of the Hepatic Acute Phase ResponseJournal of Molecular Biology, 2007
- Rapid Activation of Protein Kinase B/Akt Has a Key Role in Antiapoptotic Signaling during Liver RegenerationBiochemical and Biophysical Research Communications, 2000
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999